Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease

Michael Camilleri

INTRODUCTION

In many patients with inflammatory bowel disease (IBD), the symptoms of abdominal pain, bloating and diarrhea are out of proportion with the demonstrated degree of inflammation; some symptomatic patients may have complete mucosal healing. Such patients often may undergo invasive, costly and potentially dangerous tests in search of residual inflammation. What are the diagnostic considerations in such patients? How should they be managed?

SYMPTOMS OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH IBD IN REMISSION

Irritable bowel syndrome (IBS) is a commonly encountered disorder, with point prevalence of ~10%; symptom-based criteria facilitate its diagnosis. Although IBD affects ~0.4% of the population in the United States and Europe, IBD and IBS may concur in a patient, purely by chance. How often do patients with IBD and inflammation in remission manifest symptoms that suggest IBS, usually IBS with diarrhoea (IBS-D)?

From a database of over 1500 patients with IBD, Zaman et al identified 50 with ileal Crohn’s disease and 25 with ulcerative colitis involving only the rectosigmoid, and stable symptoms, no changes in medications or use of chronic steroids for 3 months, and no prior bowel surgery. Rome II IBS criteria were met by 67% of patients with IBD and 25 with ulcerative colitis, with similar symptoms or rectal bleeding, and may result from specific differences that require specific treatment (figure 1) rather than symptomatic treatment. The first steps are to exclude infection (eg, cytomegalovirus or Clostridium difficile infection), and to confirm that the inflammatory process is sufficiently controlled and unlikely to be the cause of symptoms.

BLOOD AND STOOL TESTS IN DISCRIMINATING IBD FROM IBS

The number of bowel movements, presence of blood in the stool, diverse activity indices, and simple blood tests such as serum C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are used to assess inflammatory activity in IBD. However, activity indices may not necessarily reflect inflammation. In the Crohn’s disease activity index (CDAI), abdominal pain, loose stools and general well-being, and the use of diphenoxylate or loperamide for diarrhoea are all manifestations of IBS with diarrhoea and may not reflect inflammation. ESR and CRP are less useful in more subtle IBD; they did not perform as well as stool calprotectin in differentiating ‘organic’ from ‘non-organic’ diseases. Table 1 summarises the ability of other blood and stool markers to discriminate IBD from IBS: faecal calprotectin, lactoferrin and S100A12 (a calcium-binding proinflammatory protein secreted by granulocytes) appear good screening tests to identify residual inflammation.

RADIOLOGICAL IMAGING

When the question of IBS in IBD arises, the patient is symptomatic and colonoscopy has usually excluded active colitis or terminal ileitis. What about small bowel inflammatory disease? Approaches to image the small bowel include barium follow through (or enteroclysis), CT enteroclysis, MR enteroclysis, or capsule endoscopy. Radiolabelled autologous leucocyte scintigraphy is used in few centres.

In general, MR and CT enterography have similar sensitivities for detecting active small bowel inflammation. MR enteroclysis may be preferred because of the absence of radiation exposure and better characterisation of stenotic lesions, whereas CT provides better temporal resolution, mesenteric imaging and shorter length of examination. MR imaging is applied for quantifying IBD severity, though further clinical validation is desirable.

IS DIARRHOEA IN IBD IN REMISSION DUE TO BILE ACID MALABSORPTION?

Hofmann and Poley showed that steatorrhoea occurs when the extent of combined ileal Crohn’s disease and resection exceeds 100 cm, with less than 100 cm of Crohn’s disease or resection, diarrhoea results from bile acid malabsorption (BAM). There are three general approaches to diagnose BAM: serum 7α-hydroxy-4-cholesten-3-one (7αC4), an indirect measurement of hepatic bile acid synthesis which is closely related to the faecal loss of bile acids; 7αC4; 48 h faecal bile acid excretion; and 75Se-HCAT (23-seleno-25-homotaurocholate, a synthetic bile acid) retention on scintigraphy, which is based on whole-body retention at 7 days of the radiolabelled bile acid and retention of <12% reflects BAM. A surrogate test is fasting serum fibroblast growth factor (FGF)19, which is reciprocally related to fasting serum 7αC4. Where the tests are not available, therapeutic trials (eg, with cholestyramine 4 g three times a day (tid); oral colesvelam 625 mg tablets, up to two tablets (tid) are indicated.

IS THERE ANOTHER CAUSE OF PERSISTENT SYMPTOMS WHEN THE IBD IS IN REMISSION?

As clinicians, we tend to apply Occam’s razor, or the law of parsimony (‘entities
Leading article

When a patient with IBD in apparent remission has symptoms suggestive of IBS

| Does the patient have rectal bleeding or constitutional symptoms e.g. fever? |
|-----------------------------|-----------------------------|
| positive | negative |
| Stool microbiology e.g. CMV, C difficile | Colonscopy Biopsy |
| Treat infection | Treat inflammation |
| positive | negative |
| Serum 7αC4; fecal bile acids; 75SeHCAT retention; therapeutic trial | Small bowel bacterial overgrowth Coeliac disease Pancreatic insufficiency Pelvic floor dyssynergia Visceral hypersensitivity Irritable bowel syndrome |
| Consider BAM | Consider another diagnosis |
| Treat BAM | Treat specific disease/disorder |

Figure 1 When a patient with inflammatory bowel disease (IBD) in apparent remission has symptoms suggestive of irritable bowel syndrome (IBS). 7αC4, 7α-hydroxy-4-cholesten-3-one; BAM, bile acid malabsorption; CMV, cytomegalovirus; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 75Se-HCAT (23-selena-25-homotaurocholate; WBC, white blood cells.

must not be multiplied beyond necessity), and apply a single diagnosis when the symptoms can all fit that diagnosis. However, just as it is possible for patients with paranoid schizophrenia to have real enemies, this principle is not irrefutable.

Symptomatic patients with IBD but without overt inflammation should be further assessed to exclude conditions that are discussed briefly here.

Small bowel bacterial overgrowth and abnormal motility in IBD

Small bowel bacterial overgrowth (SBO) is more likely to occur in Crohn’s disease, especially in the presence of strictures, fistulae or by-pass surgery with a blind loop. There is also evidence of impaired propulsive function resulting in stasis and SBO in inactive Crohn’s disease.

The diagnosis of SBO is challenging because of poor specificity of the breath hydrogen (H₂) excretion tests. For example, in 150 patients with active Crohn’s disease, 25.5% had positive glucose-H₂ breath test, and these patients reported a higher rate of abdominal complaints, increased stool frequency and lower body weight. There was no correlation with the CDAI; it is unclear why positive tests were more common (26.8%) with exclusive colitis, than with exclusive ileitis (12.8%). Ileoceleal valve resection may be a factor in breath test positivity.

Cultures of small bowel aspirates are more specific, but may be less sensitive. Ultimately, a therapeutic trial with a poorly absorbed antibiotic (eg, neomycin, metronidazole, quinolone, rifaximin) may be the most practical clinical approach in suspected SBO.

Coeliac disease

About 1 in 80 of the population has coeliac disease, the incidence being generally proportional to the prevalence of HLA DQ2 or DQ8 haplotypes. Less than 1% have IBD; these two relatively rare diseases may occur in the same patient. A database of laboratory tests for coeliac disease and ICD-9 codes for IBD (N=6908) and coeliac disease (N=512) over ~5 years identified 18 patients with both IBD and coeliac disease. These patients were more often female, commonly had extra-intestinal manifestations and more aggressive disease.

Although the concurrence of IBD and coeliac disease appears rare, it is relatively simple to screen for coeliac disease (serum tissue transglutaminase antibodies).

Pancreatic insufficiency

There is ‘functional evidence’ of pancreatic insufficiency in IBD. In 100 patients with Crohn’s disease and 100 patients with ulcerative colitis, and 100 controls, pancreatic insufficiency and its clinical course over 6-month follow-up were tested using faecal elastase-1 (FE-1). FE-1 was ≤200 μg/g stool in 22 patients with ulcerative colitis and 14 patients with Crohn’s disease. However, at 6-month follow-up, FE-1 test was normal in 24/36 patients. Persistently low stool FE-1 was associated with ≥3 bowel movements per day, loose stools, previous surgery and longer duration of disease, but not with clinically active disease.

Rarely, structural idiopathic chronic pancreatitis may occur in IBD. A 16-year experience of three hospitals in France showed eight cases with pancreatic duct stenosis, inter- and intra-lobular fibrosis, or acinar regeneration in addition to exocrine insufficiency. In that 1999 article, the literature review identified six patients with ulcerative colitis and 14 with Crohn’s disease with structural chronic pancreatitis. Painless chronic pancreatitis with exocrine insufficiency and normal or minimally altered pancreatic ducts on endoscopic retrograde cholangiopancreatography (ERCP) is also described.

In summary, pancreatic insufficiency should be considered when patients with IBD without significant ileal resection appear to be in remission, and have features suggesting steatorrhea.

Are pelvic floor dyssynergia and visceral hypersensitivity factors in IBD?

Evacuation disorders are usually confused with IBS-C, however, evacuation disorders may cause urgency and overflow diarrhoea, abdominal or pelvic pain, and bloating, which may mimic IBS-D. Involvement of the rectum and perianal structures, sometimes with fistulation in IBD, may lead to pelvic floor dysfunction (PFD) in patients with IBD. PFD has not been formally assessed in patients with active or inactive IBD. Disorders of ileal pouch evacuation may conceivably cause pouch stasis and predispose to pouchitis. Reduced pouch evacuation is usually attributed to impaired pouch contractility, though PFD has not been investigated. As in non-IBD patients, PFD should be excluded in patients with IBD with abdominal pain, bloating or constipation.

It had been postulated that IBD might predispose to afferent hypersensitivity and, therefore, to the potential for ‘IBS-like’ symptoms in patients with IBD. However, the data are conflicting, and the main papers in the literature have evaluated sensitivity in pouch patients. Shen et al suggested that some patients have ‘irritable pouch’ because scores of
Irritable bowel syndrome: a real association or reflection of occult inflammation?

Some patients with IBD who are in inflammatory remission with persistent abdominal discomfort and diarrhoea may indeed have IBS! Minderhoud et al identified Rome II IBS-like symptoms in patients with IBD in remission in a third of 73 patients with ulcerative colitis and 42% of 54 patients with Crohn’s disease who were in remission. The presence of IBS-like symptoms impaired quality of life (QOL). Simren et al documented lower levels of global well-being (PGWB) and QOL and higher levels of anxiety and depression in patients with IBD in remission who have IBS-like symptoms. Anxiety and duration of disease were significant predictors of developing IBS-like symptoms whereas age, use of chronic therapy for IBD or for BAM, and disease extent were not significant risk factors.

In a study of patients with IBD in remission (CDAI ≤150 and UCDAI ≤5, and serum CRP <10, while off corticosteroids or biologics), IBS-like symptoms were common; however, abnormal faecal calprotectin levels suggest that the mechanism in most cases was occult inflammation rather than coexistent IBS. Faecal calprotectin levels and HAD scores were higher and QOL scores lower in patients with Crohn’s disease and those with ulcerative colitis than with those without IBS-type symptoms.

Long and Drossman proposed that peripheral and central factors influence symptom generation in both IBD and IBS. However, it is still unclear what factors determine the presentation of overt inflammatory changes of IBD rather than pauci-inflammatory bowel disturbance of IBS.

CONCLUSION

In patients with IBD in remission whom residual inflammation or enteral infection are excluded, there may be another disease to which symptoms may be attributed. Effective and relatively inexpensive screening serological tests are available to exclude celiac disease and BAM. SBO can be suspected based on the anatomical derangements resulting from Crohn’s disease or the effects of bypass surgery. There is no easy, sensitive and specific test for SBO, and a therapeutic trial with a poorly absorbed antibiotic may be the most effective approach. Significant chronic pancreatic insufficiency appears to be extremely rare. Ultimately, some patients may have IBS too, and this may be a reflection of a common diathesis for IBD and IBS. In these patients, the IBS can be managed symptomatically. However, it is recommended that anti-motility agents be used judiciously to avoid potential complications of IBD.

Acknowledgement The author thanks Mrs Cindy Stanislav for excellent secretarial assistance.

Funding NIH grants R01-DK079866 and 1RC1-DK086182.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

Revised 5 January 2011
Accepted 6 January 2011

Gut 2011;60:1–4. doi:10.1136/gut.2010.234583

REFERENCES


Table 1 Biomarkers in the discrimination of irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD)

<table>
<thead>
<tr>
<th>Biomarker (ref)</th>
<th>Patients studied</th>
<th>Discrimination of IBD from IBS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faecal calprotectin</td>
<td>102 CD, 87 UC, 339 IBS</td>
<td>Abnormal calprotectin had an OR for disease of 27.8 (95% CI, 17.6 to 43.7)</td>
</tr>
<tr>
<td>Faecal calprotectin</td>
<td>Organic diarrhoea 65 (incl. 9 CD), 55 IBS</td>
<td>64% sensitivity and 80% specificity with 70% positive and 74% negative predictive values for organic causes</td>
</tr>
<tr>
<td>Faecal lactoferrin</td>
<td>104 CD, 80 UC, 31 IBS, and 56 HCs</td>
<td>90% specific for identifying inflammation in active IBD; elevated faecal lactoferrin 100% specific in ruling out IBS</td>
</tr>
<tr>
<td>Faecal calprotectin and lactoferrin</td>
<td>23 IB, 91 IBS</td>
<td>Sensitivity and negative predictive value of calprotectin both 100%, and 78% and 95%, respectively, for lactoferrin; specificity and positive predictive value slightly higher for lactoferrin</td>
</tr>
<tr>
<td>Faecal human β-defensin-2</td>
<td>30 active UC, 46 IBS, and 24 HCs</td>
<td>HBD-2 levels highest in active UC, almost as high in IBS, and lowest for HCs; accuracy for IBS versus IBD low</td>
</tr>
<tr>
<td>Faecal lactoferrin, calprotectin; blood leucocytes, CRP, and IBD antibodies</td>
<td>36 CD, 28 UC, 30 IBS, and 42 HCs</td>
<td>Overall accuracy: lactoferrin 90%, calprotectin 89%, lactate-agglutination 78%, OBTI 74%, CRP 73%, blood leucocytes 63%, CD antibodies (ASCA+/pANCA– or ASCA–/pANCA+) 55%, UC antibodies (pANCA+/pASCA–) 49%</td>
</tr>
<tr>
<td>Serum anti-flagellin antibodies</td>
<td>61 CD, 50 UC 112 IBS, and 43 HCs</td>
<td>Few patients with IBS have elevated anti-flagellin titres, at much lower titre than in CD, and slightly higher than in UC; overall diagnostic accuracy not reported</td>
</tr>
<tr>
<td>Faecal S100A12</td>
<td>64 UC, 64 CD, and 73 IBS</td>
<td>Serum level of 54.4 ng/ml could predict UC and CD with 66.7% sensitivity and 64.4% specificity</td>
</tr>
<tr>
<td>Serum S100A12</td>
<td>32 CD, 27 UC, 24 IBS, 85 infectious enteritis, 24 HCs</td>
<td>Sensitivity of 86% and specificity of 96% for distinguishing IBS from IBS</td>
</tr>
</tbody>
</table>

Overall accuracy is calculated by addition of the true-positive and true-negative test results.

ASCA, anti-Saccharomyces cerevisiae antibodies; CD, Crohn’s disease; CRP, C-reactive protein; HCs, healthy controls; OBTI, immunochromatographic test for detection of human haemoglobin; pANCA, perinuclear antineutrophil cytoplasmic antibodies; UC, ulcerative colitis.


Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease

Michael Camilleri

*Gut* published online February 2, 2011
doi: 10.1136/gut.2010.234583

Updated information and services can be found at:
http://gut.bmj.com/content/early/2011/02/02/gut.2010.234583.full.html

These include:

**References**
This article cites 42 articles, 7 of which can be accessed free at:
http://gut.bmj.com/content/early/2011/02/02/gut.2010.234583.full.html#ref-list-1

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/